James Hughes, dean of the Bloustein School of Planning & Public Policy at Rutgers University, also said he did not see much duplication to be cut.
“Allergan has a sales staff that deals with their specific products, and Pfizer has its staff for different products. So I would think that staff is going to stay intact,” Hughes said. “It shouldn’t have much of an impact one way or the other on New Jersey.”
Wall Street Journal, November 23
Report Release: Analyzing the Use and Equity of ARPA Funds in NJ Local Governments and Beyond New Jersey State Policy Lab The American Rescue Plan Act’s Coronavirus State and Local Fiscal Recovery Funds (ARPA-SLFRF) represent a historic $350 billion investment to...
Dr. Irina Grafova recently returned from the AcademyHealth Research Meeting in Minneapolis, where she had the opportunity to present two posters from the Virtual Schwartz Rounds emotional support program for nurses, run by the New Jersey Nursing Emotional Well-being...
The Heldrich Center, in conjunction with the New Jersey Economic Development Authority (NJEDA), is pleased to share a new workforce analysis of the life sciences and technology sectors in New Jersey, with a particular emphasis on the sectors’ intersection with...
Who wants a tree inventory and why? The politics of inventorying urban forestry in Galápagos, Ecuador Abstract Trees make significant contributions to the urban experience by providing ecosystem services and aesthetic value. Considering these contributions, cities are...
New Jersey State Policy Lab, Jonathan DeLura Our project to create a dataset of historical water bodies in New Jersey began by finding maps of historical water bodies. Two atlases were used to locate historical water bodies in New Jersey. The first was Atlas of the...